WASHINGTON, DC – In the wake of today’s U.S. Supreme Court decision in the United States v. Arthrex Inc. case, the Coalition Against Patent Abuse (CAPA) said that it’s critical for Congress to now address this decision and work to protect and strengthen the Inter Partes Review (IPR) within the U.S. Patent & Trademark Office (USPTO), by ensuring […]

Continue Reading

WASHINGTON D.C. – Matrix Global Advisors (MGA) released a white paper that highlights how patent thickets increase barriers for American patients to access affordable biosimilar medications and treatments.  The paper explains how some biologic manufacturers prevent competition by creating patent walls with “overlapping, weaker” patents to significantly extend their drug’s monopoly and increase profits while limiting access to […]

Continue Reading

WASHINGTON D.C. – The Coalition Against Patent Abuse (CAPA) released the following statement today after the House Committee on Oversight and Reform held a hearing entitled, “Unsustainable Drug Prices (Part III): Testimony from AbbVie CEO Richard Gonzalez,” that focuses on the company’s anti-competitive tactics and pricing strategies that keeps drug prices high for the American healthcare system and […]

Continue Reading

This Report Comes as the U.S. House Oversight and Reform Committee is Set to Hold a Hearing to Investigate Abuses by the Pharmaceutical Industry WASHINGTON D.C. – Recently, the Initiative for Medicines, Access & Knowledge (I-MAK) released a report as part of its “Overpatented, Overpriced” series on the cancer drug Keytruda, highlighting the underhanded tactics used by […]

Continue Reading

Part V: IPR & Ulcerative Colitis – Balancing Innovation and Competition Over the last year, the coronavirus pandemic has caused financial hardships for millions of Americans and our federal government continues to face unprecedented debt.  As recovery efforts are underway, the issue of skyrocketing prescription drug costs remains more prevalent than ever.  A major contributing […]

Continue Reading

Today, some major pharmaceutical companies continue to game the U.S. patent system by limiting generic competition while keeping drug prices high for millions of patients.  Big Pharma’s manipulation of patent laws prevent or delay generic medications from going to market which ultimately denies patients access to more affordable, life-saving, and quality of life enhancing drugs.  […]

Continue Reading

Part III: IPR & Opioid Addiction – Ending Brand Pharma’s Monopoly on Patents Some major pharmaceutical companies have enormous incentives to block market entry of lower-cost, generic drugs for as long as possible.  By taking advantage of certain rules or exploiting legal loopholes that extend a drug’s monopoly far beyond what Congress intended, millions of […]

Continue Reading

Part II: IPR & Zytiga – Competition Matters The rising costs of prescription drugs is one of the most important issues to Americans, especially as millions continue to grapple with financial hardships brought on by the coronavirus pandemic. Today, the U.S. pays some of the highest prices in the world for prescription drugs thanks in […]

Continue Reading

WASHINGTON, D.C. – The Coalition Against Patent Abuse (CAPA) – a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free-market advocates and others – issued a statement today following the release of a Morning Consult survey which found that Americans overwhelmingly agree that it is time for Congress and the new Administration to reform […]

Continue Reading

Part I: IPR & Insulin – The True Value of PTAB Proceedings Year after year, pharmaceutical companies engage in anticompetitive strategies to game the U.S. patent system and keep drug prices high at the expense of patients. Even as millions of Americans grapple with financial hardships brought on by the COVID-19 pandemic, these pharmaceutical companies […]

Continue Reading